{"filing":{"accession_number":"0001837607-26-000046","cik":"0001837607","ticker":"AEON","company_name":"AEON Biopharma, Inc.","form":"8-K","filing_date":"2026-06-17","report_date":null,"primary_document":"aeon-20260617x8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1837607/000183760726000046/aeon-20260617x8k.htm"},"events":[{"id":11524,"run_id":10120,"accession_number":"0001837607-26-000046","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"summary":"This is a clear Item 5.07 disclosure of shareholder vote results from AEON Biopharma's Annual Meeting of Stockholders held on June 17, 2026. The filing reports the final certified voting results for two proposals: (1) election of Class III directors Marc Forth and Seongsoo Park for three-year terms, and (2) ratification of KPMG LLP as independent auditor. Director elections and auditor ratifications are material governance matters affecting investor confidence in board composition and financial oversight.","company_name":"AEON Biopharma, Inc.","ticker":"AEON","filing_date":"2026-06-17","submitted_at":null,"items":[{"id":8128,"accession_number":"0001837607-26-000046","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a clear Item 5.07 disclosure of shareholder vote results from AEON Biopharma's Annual Meeting of Stockholders held on June 17, 2026. The filing reports the final certified voting results for two proposals: (1) election of Class III directors Marc Forth and Seongsoo Park for three-year terms, and (2) ratification of KPMG LLP as independent auditor. Director elections and auditor ratifications are material governance matters affecting investor confidence in board composition and financial oversight.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-17T20:06:18.199132+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":8128,"accession_number":"0001837607-26-000046","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a clear Item 5.07 disclosure of shareholder vote results from AEON Biopharma's Annual Meeting of Stockholders held on June 17, 2026. The filing reports the final certified voting results for two proposals: (1) election of Class III directors Marc Forth and Seongsoo Park for three-year terms, and (2) ratification of KPMG LLP as independent auditor. Director elections and auditor ratifications are material governance matters affecting investor confidence in board composition and financial oversight.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-17T20:06:18.199132+00:00","company_name":"AEON Biopharma, Inc.","ticker":"AEON","filing_date":"2026-06-17"}]}